Find Romosozumab manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

read-more
read-more

01

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 1,024,894

Year : 2023

Prescribers : 145

Prescriptions : 440

blank

02

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 71,634,311

Year : 2023

Prescribers : 6219

Prescriptions : 28510

blank

03

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 363,407

Year : 2022

Prescribers : 68

Prescriptions : 172

blank

04

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 50,051,726

Year : 2022

Prescribers : 4513

Prescriptions : 21843

blank

05

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 99,694

Year : 2021

Prescribers : 23

Prescriptions : 51

blank

06

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 29,030,405

Year : 2021

Prescribers : 3003

Prescriptions : 13840

blank

07

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 73,487

Year : 2020

Prescribers : 21

Prescriptions : 39

blank

08

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 14,428,059

Year : 2020

Prescribers : 1569

Prescriptions : 7353

blank

09

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 17,539

Year : 2019

Prescribers :

Prescriptions : 11

blank

10

arrow
AIChE Annual Meeting
Not Confirmed
arrow
AIChE Annual Meeting
Not Confirmed

Company : Amgen

Romosozumab-Aqqg

Drug Cost (USD) : 3,305,412

Year : 2019

Prescribers : 593

Prescriptions : 1690

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Annual Reports

read-more
read-more

01

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

U.S.A
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2020 Revenue in Millions : 350

2019 Revenue in Millions : 189

Growth (%) : 85

blank

02

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

Japan
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2020 Revenue in Millions : 240

2019 Revenue in Millions : 157

Growth (%) : 53

blank

03

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

Japan
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2021 Revenue in Millions : 246

2020 Revenue in Millions : 238

Growth (%) : 11

blank

04

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

Belgium
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2020 Revenue in Millions : 2

2019 Revenue in Millions : 0

Growth (%) : New Launch

blank

05

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

U.S.A
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2021 Revenue in Millions : 530

2020 Revenue in Millions : 350

Growth (%) : 51

blank

06

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

Belgium
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2021 Revenue in Millions : 11

2020 Revenue in Millions : 2

Growth (%) : 400

blank

07

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

Japan
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2022 Revenue in Millions : 302

2021 Revenue in Millions : 265

Growth (%) : 14

blank

08

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

U.S.A
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2022 Revenue in Millions : 787

2021 Revenue in Millions : 530

Growth (%) : 48

blank

09

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

Belgium
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2022 Revenue in Millions : 27

2021 Revenue in Millions : 11

Growth (%) : 142

blank

10

Brand Name : Evenity

Romosozumab

arrow
AIChE Annual Meeting
Not Confirmed

Brand Name : Evenity

U.S.A
arrow
AIChE Annual Meeting
Not Confirmed

Romosozumab

Main Therapeutic Indication : Musculoskeletal

Currency : USD

2023 Revenue in Millions : 1,160

2022 Revenue in Millions : 787

Growth (%) : 47

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty